Savant Capital LLC Acquires 9,731 Shares of DexCom, Inc. (NASDAQ:DXCM)

Savant Capital LLC boosted its holdings in DexCom, Inc. (NASDAQ:DXCMFree Report) by 9.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 110,383 shares of the medical device company’s stock after acquiring an additional 9,731 shares during the period. Savant Capital LLC’s holdings in DexCom were worth $8,584,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in DXCM. Versant Capital Management Inc bought a new position in DexCom during the 4th quarter worth $25,000. Riverview Trust Co increased its position in DexCom by 100.4% during the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock worth $31,000 after buying an additional 232 shares during the period. Heck Capital Advisors LLC bought a new position in DexCom during the 4th quarter worth $38,000. MassMutual Private Wealth & Trust FSB increased its position in DexCom by 46.7% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company’s stock worth $65,000 after buying an additional 265 shares during the period. Finally, RPg Family Wealth Advisory LLC bought a new position in DexCom during the 3rd quarter worth $57,000. Institutional investors own 97.75% of the company’s stock.

DexCom Stock Performance

NASDAQ:DXCM opened at $88.27 on Tuesday. The stock’s 50-day simple moving average is $81.76 and its 200 day simple moving average is $75.11. The firm has a market capitalization of $34.48 billion, a PE ratio of 52.86, a price-to-earnings-growth ratio of 2.26 and a beta of 1.14. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00.

Analysts Set New Price Targets

Several research analysts have weighed in on DXCM shares. Citigroup increased their price objective on DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Royal Bank of Canada lowered their price objective on DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Wells Fargo & Company increased their target price on DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a report on Wednesday, December 11th. Sanford C. Bernstein increased their target price on DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a report on Friday, October 25th. Finally, Robert W. Baird raised DexCom from a “neutral” rating to an “outperform” rating and increased their target price for the stock from $86.00 to $104.00 in a report on Thursday, January 16th. Four research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $98.41.

Read Our Latest Analysis on DexCom

Insider Activity at DexCom

In other DexCom news, COO Jacob Steven Leach sold 2,634 shares of the stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the completion of the transaction, the chief operating officer now directly owns 268,644 shares in the company, valued at approximately $23,347,850.04. This trade represents a 0.97 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Kevin R. Sayer sold 33,359 shares of the stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the completion of the transaction, the chief executive officer now owns 319,037 shares of the company’s stock, valued at $27,727,505.67. This represents a 9.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 42,342 shares of company stock valued at $3,628,069 over the last ninety days. 0.30% of the stock is owned by corporate insiders.

About DexCom

(Free Report)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Further Reading

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCMFree Report).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.